Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
The present invention relates to a class of substituted purine compounds of formula (I), uses thereof, processes for the preparation thereof and compositions containing said compounds. These compounds have utility in a variety of therapeutic areas including sexual dysfunction.(I).
N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
申请人:——
公开号:US20030105132A1
公开(公告)日:2003-06-05
The invention relates to compounds of formula (I) for treating for example sexual dysfunction, wherein R
1
is optionally substituted C
1-6
alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, hydrogen, C
1-6
alkoxy, —NR
2
R
3
or —NR
4
SO
2
R
5
; X is the linkage —(CH
2
)
n
— or —(CH
2
)
q
—O— (wherein Y is attached to the oxygen); wherein one or more hydrogen atoms in linkage X may be replaced independently by C
1-4
alkoxy; hydroxy; hydroxy(C
1-3
alkyl); C
3-7
cycloalkyl; carbocyclyl; heterocyclyl; or by C
1-4
alkyl optionally substituted by one or more fluoro or phenyl groups; n is
3, 4, 5, 6
or
7;
and q is
2, 3, 4, 5
or
6;
and Y is phenyl or pyridyl, each of which may be substituted; or two R
8
groups on adjacent carbon atoms together with the interconnecting carbon atoms may form a fused optionally substituted
5
- or
6
-membered carbocyclic or heterocyclyic ring.
1
New indazole and indolone derivatives and their use pharmaceuticals
申请人:Allerton Norfor Charlotte Moira
公开号:US20050267096A1
公开(公告)日:2005-12-01
The present invention provides for compounds of formula (I),
which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and/or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD; lack of interest in sex), female orgasmic disorder (FOD; inability to achieve orgasm); and male sexual dysfunction, in particular male erectile dysfunction (MED). Male sexual dysfunction as referred to herein is meant to include ejaculatory disorders such as premature ejaculation, anorgasmia (inability to achieve orgasm) or desire disorders such as hypoactive sexual desire disorder (HSDD; lack of interest in sex). These compounds are also useful in treating neuropsychiatric disorders and neurodegenerative disorders.
The present invention relates to a class of melanocortin MCR4 agonists of general formula (I)
wherein R
1
, R
2
, R
3
, R
4
and R
5
are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.